During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

It’s one of the few cancers still considered incurable, and those diagnosed with multiple myeloma will likely die from the ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Monitoring and analyzing gut microbes may help predict how myeloma patients will respond to CAR T-cell therapy, research ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer ...